Homozygous Familial Hypercholesterolemia (HoFH) Market is Predicted to Exhibit Remarkable Growth Across the APAC Region by 2034, Analyzes DelveInsight | Alnylam, Akeso Biopharma, Innovent Biologics, LIB Therapeutics LLC, and Novartis

DelveInsight's "Homozygous Familial Hypercholesterolemia (HoFH) - Patient Pool Analysis, Market Size, and Market Forecast APAC, 2034" report provides comprehensive insights into the historical and projected patient burden, treatable patient population, and notable market trends across the APAC region (India, China, South Korea, Taiwan, and Australia), highlighting distinctions from established markets.

The APAC Homozygous Familial Hypercholesterolemia market report also offers insights into current treatment patterns, emerging prominent players, market shares of approved drugs, and peak share estimates for upcoming therapies. It covers historical and forecasted Homozygous Familial Hypercholesterolemia market size, share, and trends in the Asia-Pacific region (India, China, South Korea, Taiwan, and Australia) during the study period (2020-2034). Additionally, the report examines recent treatment practices, therapy compliance, and accessibility, identifying unmet needs and evaluating market potential.

Homozygous Familial Hypercholesterolemia (HoFH): An Overview
HoFH is a rare and severe genetic disorder that affects cholesterol metabolism. It is an inherited condition caused by mutations in both copies of the (low-density lipoprotein receptor) LDLR gene or other genes related to cholesterol metabolism, such as the APOB or PCSK9 genes. The LDLR gene encodes a receptor responsible for removing low-density lipoprotein (LDL) cholesterol from the bloodstream. Mutations in both copies of LDLR severely impair the function of these receptors, resulting in extremely high levels of LDL cholesterol in the blood. Individuals have high cholesterol levels despite following a low-cholesterol diet and other lifestyle modifications.

The disease is characterized by plasma cholesterol levels higher than 13 mmol/L (>500mg/dL), corneal arcus, xanthomas, xanthelasmas, and marked premature and progressive atherosclerotic cardiovascular disease. It is typically diagnosed early in life, and high LDL cholesterol levels increase the risk of cardiovascular complications such as heart attacks and strokes at a young age.

The diagnosis involves a combination of clinical evaluation, lipid profile testing, and genetic testing. Due to its extreme rarity and potentially severe consequences, early and accurate diagnosis is crucial for timely intervention and management. Treatment typically involves a combination of lipid-lowering medications, lifestyle modifications, and in some cases, advanced interventions.

Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook (APAC Region)
The market for Homozygous Familial Hypercholesterolemia (HoFH) in the Asia Pacific region is rapidly advancing due to increased awareness and collaborative efforts among healthcare professionals and stakeholders. HoFH, a rare genetic disorder characterized by exceptionally high LDL cholesterol levels, traditionally relied on aggressive cholesterol-lowering therapies like statins and PCSK9 inhibitors.

However, recent innovations such as LDL apheresis and gene therapy offer promising new treatment avenues. With improved access to genetic testing and heightened awareness campaigns, early diagnosis and personalized treatment plans are becoming more common. Collaboration between healthcare providers, advocacy groups, and pharmaceutical companies is essential for raising awareness and advocating for access to these innovative treatments. Despite challenges like limited access to specialized care and high treatment costs, ongoing efforts aim to ensure comprehensive and timely care for individuals affected by HoFH in the region. Overall, the evolving market for HoFH in Asia Pacific holds promise for better management and improved outcomes for patients with this rare genetic disorder.

Get a Detailed Overview of the Evolving Homozygous Familial Hypercholesterolemia Market Trends @
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia (HoFH) Market
The Homozygous Familial Hypercholesterolemia Market is poised for significant evolution, particularly within Asia-Pacific countries. This shift is underscored by the market outlook section of the report, which aims to enhance comprehension by delving into historical, present, and forecasted market projections. By examining the influence of both markets and emerging therapies, the report offers insights into the transformative forces at play. Furthermore, it conducts a thorough examination of the drivers, barriers, unmet needs, and emerging technologies within the Homozygous Familial Hypercholesterolemia market landscape.

The report comprehensively outlines the market trends associated with every Homozygous Familial Hypercholesterolemia drug currently available in the market and those in late-stage pipeline (i.e. Phase III stage) development. This thorough analysis encompasses various facets such as the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competitive landscape vis-à-vis other therapies, brand reputation, and their overall influence on the market dynamics. Furthermore, it incorporates insights from key opinion leaders, providing a holistic view of the market scenario.

Discover How the Homozygous Familial Hypercholesterolemia Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia (HoFH) Epidemiology
The prevalence of Homozygous Familial Hypercholesterolemia differs significantly across the APAC countries (India, China, South Korea, Taiwan, and Australia), influenced by a multitude of factors including genetics, demographics, lifestyle choices, and environmental elements. Within the report's epidemiology section, a comprehensive examination of patient burdens within each Asia-Pacific country is provided, encompassing historical, present, and projected trends. This analysis not only addresses the diagnosed and treated patient populations but also delves into sub-segments such as age-specific and gender-specific demographics, offering a nuanced understanding of the disease landscape within the region.

Get Key Insights Into the Evolving Homozygous Familial Hypercholesterolemia Epidemiology Trends @
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia (HoFH) Drugs Uptake and Pipeline Development Activities
Numerous leading pharmaceutical and biotechnology firms are actively engaged in developing therapies for Homozygous Familial Hypercholesterolemia. This section of the Homozygous Familial Hypercholesterolemia market report offers detailed insights into each therapy approved within the APAC countries, provided the therapy retains patent protection or market exclusivity in at least one APAC nation. Notably, off-label, generic, and biosimilar treatments are consolidated within the preceding treatment section of the report. Within this section, both marketed and late-stage (Phase III and Phase II) pipeline drugs are scrutinized, while early-phase drugs are presented in tabular format for clarity and accessibility.

Every Homozygous Familial Hypercholesterolemia drug chapter within the report will encompass a comprehensive overview, comprising detailed descriptions, clinical trial evaluations, insights into research and development initiatives, as well as analyses of agreements and collaborations pertinent to each drug. Moreover, the chapters will delve into approval status, patent particulars, and a thorough examination of the advantages and disadvantages associated with each drug. Additionally, the report covers the latest updates and news pertaining to each product, ensuring a well-rounded understanding of the current landscape surrounding these therapies.

Explore More About Ongoing Pipeline Development Activities in the Homozygous Familial Hypercholesterolemia Market @
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Assessment
Novel therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, angiopoietin like-3(ANGPTL3) inhibitors, and MTP inhibitors have developed in recent decades. These enable the possibility of achieving LDL cholesterol goals in HoFH patients. Various therapies have been approved in the last decade. These include Ultragenyx and Regeneron's EVKEEZA (evinacumab), Chiesi Farmaceutici/Recordati's JUXTAPID/LOJUXTA (lomitapide), Amgen's REPATHA (evolocumab), and Regeneron/Sanofi's PRALUENT(alirocumab). Most of these are adjunct to the current lipid-lowering first-line therapies. The US FDA also approved Mipomersen, but it is no longer available.

Despite the recent approvals of new therapies, decreasing LDL-C in HoFH patients remains difficult. Newer, more potent, and better tolerated LDL lowering therapies are needed to prevent atherosclerotic cardiovascular disease in these genetically challenged patients.

Several major pharma and biotech companies are at the forefront of developing therapies for Homozygous Familial Hypercholesterolemia (HoFH). Among these companies, some have advanced their HoFH drug candidates to the most critical stages of development, notably Phase II clinical trials. One such company making significant strides in this area is Arrowhead Pharmaceuticals. By focusing on Phase II trials, Arrowhead Pharmaceuticals demonstrates a commitment to advancing potential treatments for HoFH, addressing the urgent medical needs of individuals affected by this rare and severe genetic disorder. Alongside Arrowhead Pharmaceuticals, other pharmaceutical and biotech companies are also actively engaged in research and development efforts aimed at providing effective therapeutic options for HoFH patients.

Leading Companies in the Homozygous Familial Hypercholesterolemia Therapeutics Market Include
• Alnylam Pharmaceuticals
• Akeso Biopharma
• Innovent Biologics
• LIB Therapeutics LLC
• Novartis
And Many Others

Emerging and Marketed Homozygous Familial Hypercholesterolemia (HoFH) Therapies Covered in the Report Include
• Tafolecimab: Innovent Biologics
• ARO-ANG3: Arrowhead Pharmaceuticals
• LEQVIO (inclisiran/KJX839): Novartis/Alnylam Pharmaceuticals
• EVKEEZA (evinacumab): Regeneron/Ultragenyx
• JUXTAPID/LOJUXTA (lomitapide): Chiesi Farmaceutici/Recordati
• PRALUENT (alirocumab): Regeneron/Sanofi
• REPATHA (evolocumab): Amgen
And Many More

Learn More About the Emerging Therapies and key Companies in the Homozygous Familial Hypercholesterolemia Therapeutics Market @
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Homozygous Familial Hypercholesterolemia Disease Background and Overview
8. APAC Homozygous Familial Hypercholesterolemia Patient Pool Analysis
9. APAC Homozygous Familial Hypercholesterolemia Patient Journey
10. Marketed Homozygous Familial Hypercholesterolemia Therapies
11. Emerging Homozygous Familial Hypercholesterolemia Therapies
12. Homozygous Familial Hypercholesterolemia APAC Market Analysis
13. Access and Reimbursement Scenario
14. KOL's Views on Homozygous Familial Hypercholesterolemia Market
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.